Riboflavin and Ajovy drug interactions - a phase IV clinical study of FDA data


Drug interactions are reported among 24 people who take Riboflavin and Ajovy. Common interactions include seizure among females, and abdominal pain upper among males.

The phase IV clinical study analyzes what interactions people who take Riboflavin and Ajovy have. It is created by eHealthMe based on reports from the FDA, and is updated regularly. You may use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 700+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Sep, 26, 2023

24 people who take Riboflavin and Ajovy together, and have interactions are studied.

What is Riboflavin?

Riboflavin has active ingredients of riboflavin (vitamin b2). It is used in migraine. Currently, eHealthMe is studying from 2,463 Riboflavin users.

What is Ajovy?

Ajovy has active ingredients of fremanezumab-vfrm. Currently, eHealthMe is studying from 7,343 Ajovy users.

Number of Riboflavin and Ajovy reports submitted per year:

Riboflavin and Ajovy drug interactions.

Common Riboflavin and Ajovy drug interactions by gender *:


  1. Seizure
  2. Anxiety
  3. Influenza
  4. Staphylococcal infection
  5. Visual impairment
  6. Paraesthesia
  7. Infusion related reaction
  8. Infusion site extravasation
  9. Myalgia
  10. Pruritus


  1. Abdominal pain upper
  2. Drug intolerance
  3. Dyspepsia
  4. Nausea

Common Riboflavin and Ajovy drug interactions by age *:








  1. Nausea
  2. Seizure
  3. Anxiety
  4. Visual impairment
  5. Myalgia
  6. Abdominal pain upper
  7. Drug intolerance
  8. Dyspepsia
  9. Bedridden
  10. Cerebrovascular accident


  1. Pruritus
  2. Rash
  3. Disturbance in attention
  4. Headache
  5. Injection site erythema
  6. Injection site pruritus
  7. Injection site rash
  8. Injection site urticaria
  9. Joint swelling
  10. Oedema peripheral


  1. Adenovirus infection
  2. Back injury
  3. Back pain
  4. Chest discomfort
  5. Chills
  6. Contusion
  7. Cough
  8. Dysuria
  9. Ear disorder
  10. Fatigue


  1. Rectal prolapse
  2. Upper respiratory tract infection
  3. Pain of skin
  4. Balance disorder
  5. Dyspnoea
  6. Ear discomfort
  7. Hypoacusis
  8. Hypoaesthesia
  9. Knee arthroplasty
  10. Lung disorder



Common conditions people have *:

  1. Immunodeficiency Common Variable: 7 people, 29.17%
  2. Relapsing-Remitting Multiple Sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 4 people, 16.67%
  3. Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 3 people, 12.50%

* Approximation only. Some reports may have incomplete information.

Do you take Riboflavin and Ajovy?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

Drug side effects by duration, gender and age:

Common Riboflavin drug interactions:

Browse interactions between Riboflavin and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Ajovy drug interactions:

Browse interactions between Ajovy and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on riboflavin (vitamin b2) and fremanezumab-vfrm (the active ingredients of Riboflavin and Ajovy, respectively), and Riboflavin and Ajovy (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Riboflavin and Ajovy.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 700+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).


WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: